This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
This two-day program was attended by 40 doctors & paramedical staff
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
The partnership marks a significant milestone in integrating digital health education into medical curricula
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Morepen Labs successfully raised Rs. 200 Crore through QIP
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Subscribe To Our Newsletter & Stay Updated
